Could a Ketamine-Like drug ease OCD? new trial underway
NCT ID NCT06575075
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This study tests a new drug called RR-HNK (related to ketamine) to see if it safely reduces obsessive-compulsive disorder (OCD) symptoms. About 45 adults with OCD who haven't improved with standard treatments will receive two doses of the drug or a placebo. The main goal is to measure changes in OCD severity using a standard scale.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSESSIVE-COMPULSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Stanford University School of Medicine
RECRUITINGPalo Alto, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single ketamine infusion quiet the obsessive mind?
- Can improv comedy help tame OCD?
- A Two-Year watch: can brain scans and surveys predict depression and anxiety in teens?
- Therapy may let kids with OCD ditch meds for good
- Could gut bacteria hold the key to childhood OCD?
- Can brain recordings unlock better OCD treatment?